RT Journal Article
T1 The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
A1 López Millán, Belén
A1 Costales, Paula
A1 Gutiérrez Agüera, Francisco
A1 Díaz de la Guardia, Rafael
A1 Roca Ho, Heleia
A1 Vinyoles, Meritxell
A1 Rubio Gayarre, Alba
A1 Safi, Rémi
A1 Castaño, Julio
A1 Romecín, Paola Alejandra
A1 Ramirez Orellana, Manuel
A1 Anguita Mandly, Eduardo Luis
A1 Jeremías, Irmela
A1 Zamora, Lurdes
A1 Rodríguez Manzaneque, Juan Carlos
A1 Bueno, Clara
A1 Morís, Francisco
A1 Menéndez, Pablo
AB Patients with AML harboring constitutively active mutations in the FLT3 receptor generally have a poor prognosis (FLT3-ITDMUT). Despite the fact that several FLT3 inhibitors have been developed, clinical responses are commonly partial or not durable, highlighting the need for new molecules targeting FLT3-ITDMUT. Here, we tested EC-70124, a hybrid indolocarbazole analog from the same chemical space as midostaurin (a well-known FLT3 inhibitor). Our in vitro and in vivo experiments showed that EC-70124 exerts a robust and specific antileukemia activity against FLT3-ITDMUT AML cells while sparing healthy hematopoietic cells. Collectively, EC-70124 is a promising and safe agent for the treatment of this aggressive type of AML.
PB MPDI
SN 2072-6694
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/71621
UL https://hdl.handle.net/20.500.14352/71621
LA eng
NO Lopez Millán, B., Costales, P., Gutiérrez Agüera, F. et al. «The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia». Cancers, vol. 14, n.o 6, marzo de 2022, p. 1593. DOI.org (Crossref), https://doi.org/10.3390/cancers14061593.
NO Ministerio de Economía, Comercio y Empresa (España)
DS Docta Complutense
RD 21 abr 2025